## **LEGEND-T2DM Evidence Dissemination Summary**

Target: exenatide, Comparator: empagliflozin Outcome: Bone fracture Subgroup: All


## How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	2,290	1,280	27	21.09
Clinformatics	1,876	1,133	33	29.11
DA Germany	-	-	-	-
LDP France	-	-	-	-
MDCD	596	291	12	41.27
MDCR	161	59	<5	<84.55
Open Claims	0	0	0	NaN
Optum EHR	2,664	1,108	12	10.83
Veterans Affairs	-	-	-	-

## How Reliable Are the Effect Estimates? (Objective diagnostics) Comparator Target ■ Before ■ After MDRR Negative control Calibrated estimate Equipoise = 0.31 Max ASDM = 0.10MDRR = 1.7EASE = 0.07 • 1.26(0.75 - 2.13)CCAE Max ASDM = 0.10Equipoise = 0.38 MDRR = 1.60.78 (0.48 - 1.27) Clinformatics



**DA Germany** 



## What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

